Newbury Pharmaceuticals Ab Stock Net Asset
| NEWBRY Stock | 3.44 0.08 2.38% |
Newbury Pharmaceuticals AB fundamentals help investors to digest information that contributes to Newbury Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Newbury Stock. The fundamental analysis module provides a way to measure Newbury Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Newbury Pharmaceuticals stock.
Newbury |
Newbury Pharmaceuticals AB Company Net Asset Analysis
Newbury Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Newbury Pharmaceuticals Net Asset | 86.91 M |
Most of Newbury Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Newbury Pharmaceuticals AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Newbury Pharmaceuticals AB has a Net Asset of 86.91 M. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The net asset for all Sweden stocks is notably lower than that of the firm.
Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
Newbury Fundamentals
| Return On Equity | -0.34 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (2.89) % | |||
| Operating Margin | (2.75) % | |||
| Current Valuation | 96.57 M | |||
| Shares Outstanding | 19.52 M | |||
| Shares Owned By Insiders | 78.64 % | |||
| Shares Owned By Institutions | 6.72 % | |||
| Price To Book | 1.86 X | |||
| Price To Sales | 25.09 X | |||
| Revenue | 5.77 M | |||
| Gross Profit | 1.56 M | |||
| EBITDA | (15.74 M) | |||
| Book Value Per Share | 3.24 X | |||
| Target Price | 8.5 | |||
| Market Capitalization | 110.88 M | |||
| Total Asset | 86.91 M | |||
| Net Asset | 86.91 M |
About Newbury Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Newbury Pharmaceuticals AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Newbury Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Newbury Pharmaceuticals AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Newbury Stock
Newbury Pharmaceuticals financial ratios help investors to determine whether Newbury Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Newbury with respect to the benefits of owning Newbury Pharmaceuticals security.